Acutaas Chemicals Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Revenue surged 59% YoY, margin nearly doubled: Revenue hit ₹329.7 cr while EBITDA margin expanded 973 bps YoY to 34.3%, powered by the Pharma Intermediates segment and operating leverage.
• Battery chemicals moved from promise to production: The trial run is complete, commercial supply has begun, and management expects a rapid quarter-on-quarter ramp starting Q2, calling demand "unprecedented."
• CDMO ambition is scaling up, not down: Management is "confident to beat" its ₹1,000 cr CDMO revenue target, with four validated products set to contribute from H2 FY27 and a pipeline of 30-40 new molecules developed annually.
• The growth engine is diversifying on purpose: Pharma Intermediates will shrink from 87% to ~80% of revenue over three years as battery chemicals and semiconductor materials (Indichem) come online, while overall EBITDA margin is targeted to hold steady at the higher revenue base.
• What to watch next quarter: The pace of the battery chemicals ramp, any quantification of that revenue, progress on the Indichem semiconductor plant capex (due for completion by end of Q2), and whether the Specialty Chemicals segment stabilizes as commodity products are phased out.

The Quarter: What Drove It

• Pharma Intermediates dominated: The segment grew 76.5% YoY to ₹292.7 cr, with both CDMO and core Pharmaceutical Intermediates contributing strongly. A couple of new products gained volume traction alongside top products.
• Gross margin jumped on mix: Gross margin expanded 466 bps YoY to 57.9%, driven by a higher contribution from the Pharma Intermediate business compared to the same period last year.
• EBITDA more than doubled: EBITDA margin reached 34.3%, up 973 bps YoY, as gross margin expansion combined with operational efficiencies. Savings from a solar project also helped.
• Specialty Chemicals declined as planned: Revenue fell 10.6% YoY to ₹37 cr as the company phased out commodity chemicals. A strong recovery in the BFC business was offset by that decline, in line with expectations.
• Employee costs rose on increments and bonuses: Annual increments were rolled out and onetime performance bonuses were paid, lifting employee cost for the quarter. Other expenses remained in line with previous quarters.
• Other income dropped sharply: Other income fell from ~₹11 cr to ~₹1.8 cr because the previous quarter included a ₹10 cr positive euro exchange fluctuation; the current quarter had only ₹10 lakhs of positive fluctuation.
• Working capital days ticked up: Working capital increased to 99 days from 91 days in Q4 FY26, as improvements in debtors and creditors were offset by higher inventory days.

Naresh Patel: "What we are seeing is that AI is starting to push CPU demand higher and that's pulling memory chip demand up right along with it. At a time when supply is already tight. To us, this isn't the passing phase. It is a structural phase."

Battery Chemicals: The New Growth Engine Fires

• Trial run complete, commercial supply started: The battery chemicals plant successfully completed its trial run and began commercial supply. Revenue has already been recognized, though management declined to quantify it.
• Rapid ramp expected: Management expects production to ramp quarter-on-quarter from Q2 through Q4, with supply contracts already in place with the customer. Demand is described as "unprecedented" and driven by tight global supply.
• Capacity, not demand, is the constraint: The business is not constrained by market demand but by plant capacity. Full capacity utilization is expected within three years, and management is "more than confident" of achieving that.
• Third battery product near contract signing: A third product has been developed and is in the final stage of signing a long-term supply contract. Once signed, capex for a fourth product will be planned based on the customer's quantity requirements.
• Phase 2 electrolyte additives on schedule: Capex for the third electrolyte additive product is expected to be completed by end of Q2 FY27, with trial runs to commission soon after. A signed contract is in place, and ramp-up is expected in FY28.
• 10% stake given to business partner in electrolyte subsidiary: The dilution to ARZ was equity awarded to a partner responsible for business development and sales of electrolyte additive products since the start of the business.

Naresh Patel: "Demand here is unprecedented, driven by tight global supply and we, therefore, expect a rapid ramp-up over the coming quarters."

CDMO: The Pipeline Behind the ₹1,000 cr Target

• Confident to beat the target: Management reiterated its ₹1,000 cr CDMO revenue target and stated it is "very much confident to not only achieve this target... we are confident to beat this target," based on the upcoming product pipeline.
• Four validated products ready to convert: Four CDMO products are already validated with regulatory approval in place. Revenue from these is expected to kick in from H2 FY27 onwards.
• 30-40 new molecules developed annually: The company develops around 30-40 molecules each year and submits them to different customers at various stages of investigation. Some progress to later phases, building a long-term pipeline.
• Revenue concentration will dilute over time: Multiple projects in the R&D pipeline will slowly derisk revenue concentration from any single product as new CDMO and other products keep adding to the basket.
• Apixaban picking up: The product has already started gaining traction, and sufficient capacity exists to cater to demand.
• CDMO project details withheld: Management declined to share therapeutic areas, chemistries, or how inquiries come, citing confidentiality agreements with customers.

Abhishek Patel: "We have already guided the market that we would be hitting INR1,000 crores revenue from our CDMO business. That is based on our confidence and looking at our upcoming product pipeline for our CDMO business. And we are very much confident to not only achieve this target. And in fact, we are confident to beat this target."

Indichem: The Semiconductor Bet Takes Shape

• R&D facility commissioned, product development underway: The R&D facility is operational, and product development and business development work has started. Management expects this to reduce time-to-commercialization.
• Plant capex on track for Q2 FY27 completion: The Indichem plant capex is expected to be completed by end of Q2 FY27, with revenue expected from FY28 onwards.
• Slow start, then a multi-year fill: Management expects a slow start because it is a new business, but anticipates filling full capacity at Indichem in three to four years.
• Product details beyond photoresist chemicals withheld: Management confirmed there are multiple projects but declined to share specifics on what products will be manufactured.
• Margin profile still undefined: Management said it is too premature to give any steady-state margin number for Indichem, but suggested benchmarking against the BFC product margin rather than Pharma Intermediates.

Margins, Mix & Capital Allocation

• FY27 margin target: hold the line at a higher base: Management is targeting a similar overall EBITDA margin for FY27 as FY26, even at a higher revenue base, as the increasing CDMO contribution is offset by the ramp of the lower-margin battery business.
• Product rationalization continues: Pharma Intermediates rationalization was completed in FY26. In FY27, restructuring is happening in the old commodity chemical portfolio, with newer higher-margin products replacing them.
• Specialty Chemicals not expected to decline for the full year: Commodity chemical revenue will keep declining, but management expects this to be more than offset by growth in BFC, new revenue from battery chemicals, and new specialty chemical products with better margins.
• FY27 capex: spillover plus maintenance, with more to come: Spillover capex for electrolyte additives and a pilot plant total ~₹50 cr, plus ₹40-45 cr of maintenance capex. Additional capex for a new R&D center and land acquisition for future expansion will be announced once finalized.
• Land acquisition targets Pharma Intermediates capacity: The Sachin plant is hitting its capacity utilization roof, and the Ankleshwar plant is expected to fill up by FY28. New land is needed for future capacity and newer chemical projects.
• Revenue mix to shift over three years: Pharma Intermediate revenue composition is expected to come down to around 80% from 87% over the next three years as battery and semiconductor businesses scale.
• No forward integration into APIs or electrolyte salts: Management explicitly ruled out moving up the value chain into APIs or expanding into electrolyte salts or solutions, citing a policy of not competing with customers.

Abhishek Patel: "We do not compete our customer. That's our policy, and we would like to stick to it."

Capacity & Operational Footing

• Capacity utilization varied by site: Sachin unit ran at 83%, Ankleshwar Unit 2 at 23%, and Jhagadia Unit 3 at 55% for the quarter. The Ankleshwar plant is expected to fill up by FY28.
• Battery business is capacity-constrained, not demand-constrained: Management stated plainly that the battery chemicals business is constrained by plant capacity, not by market demand, which it called "huge."
• Electrolyte additive plant already generating revenue: Trial batches from the plant are complete, and revenue has already started.
• Certifications secured: The company received Great Place to Work certification and Responsible Care certification from the Indian Chemical Council.

Abhishek Patel: "This business is not constrained by the demand in the market. There is a huge demand available. It is constrained by our plant capacity."

Guidance & Commitments

Key Metrics